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Background: Poly (ADP-ribose) polymerase 1 (PARP1) overexpression plays a critical role in ovarian cancer
progression and the clinical development of PARP1 inhibitors to treat BRCA-mutated ovarian cancer has advanced
rapidly. However, the mechanism regulating PARP1 expression remains unknown. Alterations in gene expression
mediated by promoter methylation are being increasingly recognized and have frequently been reported in ovarian
cancer. We therefore investigated the methylation status of the PARP1 promoter region and its correlation with
PARP1 expression in BRCA-mutated ovarian cancer.
Methods: DNA from BRCA-mutated serous ovarian cancer samples and adjacent normal ovarian tissues were
analyzed by bisulfite sequence using primers focusing on the CpG island in the promoter region of PARP1.
Expression levels of PARP1 were assessed by immunohistochemistry and real-time PCR.
Results: Serous ovarian cancer tissues displayed decreased DNA methylation in the promoter region of PARP1
compared to normal tissue, and methylation intensity correlated inversely with PARP1 mRNA levels. More
importantly, E26 transformation-specific (ETS) defined CpG sites were significantly less methylated in ovarian cancer
samples.
Conclusions: These results indicate that hypomethylation of the promoter region, especially around the ETS motif
might play a role in the upregulation of PARP1 expression in the progression of ovarian cancer.
Keywords: PARP1, ETS, BRCA mutation, Ovarian cancer, MethylationBackground
Ovarian cancer is the most lethal gynecological malig-
nancy in the United States [1]. To date, although the
exact cause of ovarian cancer is not clear, BRCA1 and
BRCA 2 mutations are the only known causes of heredi-
tary ovarian cancer [2]. In 2005, two pivotal studies
showed that BRCA-deficient cells were especially sensi-
tive to chemical inhibitors of poly (ADP-ribose) poly-
merase (PARP), which plays a critical role in single-
stranded DNA break repair, presumably due to the lack* Correspondence: biff@yahoo.cn
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reproduction in any medium, provided the orof homologous recombination-dependent DNA repair
[3,4]. These findings have raised significant concerns
about PARP and PARP inhibitors in ovarian cancer. Re-
cently, emerging evidence has indicated that PARP ex-
pression is frequently upregulated in ovarian cancer and
is related to worse overall survival [5,6]. However, little
is known about the mechanisms regulating PARP gene
transcription. In mammals, methylation of cytosine in
CpG dinucleotides (especially those located in promoter
regions) is an important feature regulating gene expres-
sion [7]. Notably, Several lines of data have suggested
that PARP1 promoter methylation is involved in the
regulation of nano-SiO2-induced decrease of PARP1 ex-
pression in HaCaT cells [8] and benzene-induced de-
crease of PARP1 expression in lymphoblastoid cell linehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methylation patterns in the PARP1 promoter region in
BRCA-mutated ovarian cancer, showing that abnormal
hypomethylation of this promoter, especially around the
E26 transformation-specific (ETS) motif, may be respon-
sible for PARP1 overexpression.
Methods
Patients
This study was approved by the Institutional Review
Board at China Medical University. Serous ovarian can-
cer patients were enrolled between 2010 and 2012, and
all patients gave informed consent. Fresh tumor samples,
adjacent normal ovarian tissues and blood samples were
obtained at the time of primary surgery before any
chemotherapy or radiotherapy. Hematoxylin and eosin
staining of the samples for histopathological diagnosis and
grading were determined by three staff pathologists using
the World Health Organization criteria. All patients were
screened for BRCA1 and 2 mutations by multiplex poly-
merase chain reaction with complete sequence analysis as
previously reported [10-12]. Briefly, genomic DNA iso-
lated from peripheral blood leukocytes were amplified
using specific primers and the amplified products were
then sequence analyzed. At the end, ten patients were
determined to have a BRCA-mutation. Their characte-
ristics are given in Additional file 1.
Real-time quantitative PCR
Total RNA was extracted from the tumor and normal
ovarian tissues using Trizol reagents (Invitrogen, Carls-
bad, CA) according to the manufacturer’s protocol. It
was then reverse transcribed using the PrimeScript RT
Master Mix kit (TaKaRa, Dalian, China) and amplified
by SYBR Premix Ex TaqTM II (TaKaRa) in a Roche
LightCycler 2.0 instrument (Roche Diagnostics, Mann-
heim, Germany). The specific primer sequences were as
follows: PARP1: 50- GAGTCGGCGATCTTGGACC -30
(F) and 50- TGACCCGAGCATTCCTCG -30 (R); GAPDH:
50- AGGTGAAGGTCGGAGTCA -30 (F) and 50- GGTC
ATTGATGGCAACAA -30(R). GAPDH mRNA was amp-
lified as an internal control for normalization of each sam-
ple. The PCR cycling conditions were: 45 cycles of 10 s at
95°C, 20 s at 60°C. For all transcripts, the melting curve
was obtained after cycling at a stepwise increase in
temperature from 55 to 95°C to verify the specificity of
amplification. The threshold cycle (Ct) was used to repre-
sent the relative mRNA amounts. All samples were
analyzed in triplicate using the 2–ΔΔCT method.
Immunohistochemistry
The standard SP kit (Zhongshan, Beijing, China) was used
for immunohistochemical staining. Briefly, serial 4-μm
sections were obtained from each paraffin-embeddedtissue block. Following deparaffinization and rehydration,
sections were subjected to microwave antigen retrieval.
The primary antibody was mouse monoclonal anti-PARP1
(1:100; Santa, Cruz Biotechnologies, USA) and the
sections were incubated overnight at 4°C with this anti-
body. 3, 3'-diaminobenzidine (DAB) was used as the
chromogen. Nuclei were counterstained with hematoxylin,
and slides were dried and mounted. Negative controls
were incubated with phosphate-buffered saline (PBS) in-
stead of the antibody. Immunostaining was evaluated by
two independent pathologists, blinded to the identity of
subject groups. Area quantification was made with a light
microscope at a magnification of 400 × and analyzed by
Image-Pro Plus 6.0 (Media 2 Cybernetics, USA) using
PARP1-positive cells.
Bisulfite sequencing
Genomic DNA extracted from ovarian carcinoma and
normal ovarian tissues with a TIANamp Genomic DNA
kit (Tiangen biotech, Beijing, China) was subjected to
bisulfite conversion using the EZ DNA Methylation-
Direct kit (Zymo research, Orange, USA) following the
manufacturer’s instructions, the conversion efficiency
was estimated to be at least 99.6%. It was then amplified
by nested PCR. After gel purification, cloning and trans-
formation into E.coli Competent Cells JM109 (TaKaRa),
ten positive clones of each sample were sequenced to as-
certain the methylation patterns of each CpG locus. The
following primers were used: round I, F: 50- TTGGGAT
AGAATAATTAAAG -30 and R: 50- AACTTTTCCTACA
ACATCAA -30; and round II, F: 50- TAGAATAATTA
AAGGGGTGG -30 and R: 50- ACAACATCAACAAAA
CCTT -30. The conditions were as follows: 95°C for 2 min,
40 cycles of 30s at 95°C, 30s at 56°C and 45 s at 72°C, then
72°C for 7 min.
Statistical analysis
The data are presented as mean ± SD. Statistical diffe-
rences in the data were evaluated by paired Student’s t
test, and were considered significant at P < 0.05.
Results
PARP1 expression was upregulated in BRCA-mutated
ovarian cancer
Real-time PCR and immunohistochemical analysis showed
that PARP1 mRNA and protein were overexpressed in
ovarian cancer tissues, compared to normal ovarian tissues
(P < 0.05; each group n = 10; Figure 1A and B).
BRCA-mutated ovarian cancer tissues displayed a highly
hypomethylated ETS motif and promoter region
To investigate PARP1 transcriptional regulation through
epigenetic mechanisms, we assessed the essential regula-
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Figure 1 Overexpression of PARP1 mRNA and protein in BRCA-mutated ovarian cancer. A, Relative PARP1 mRNA levels were measured by
real-time quantitative PCR. B i, Sections were subjected to immunostaining for PARP1 in normal and ovarian cancer tissue. Arrow shows positive
staining for PARP1 in the nuclei. B ii, Summary of the percentages of PARP1-positive cells from the measurements shown in (B i). Bar graphs
show mean ± SD. Magnification is 400 × .


















































































Figure 2 Hypomethylation of the ETS motif and promoter region of PARP1 in BRCA-mutated ovarian cancer. A, Location of PARP1 core
promoter CpG sites. Genomic coordinates are shown, along with the primer-amplified fragments, GC percentage, location of individual CpG
dinucleotides (dashes), CpG island (green bar), and the PARP1 RefSeq gene (exon 1 shown as a blue box and intron shown as an arrowed line).
The arrow indicates the transcriptional direction. B, Changes of methylation patterns in the core promoter region of PARP1 (each group, n = 10).
The circles correspond to CpG sites denoted by the black dashes in (A). Closed circles, methylation; open circles, unmethylation. Ten individual
clones were sequenced for each sample. Red circles show a methylation of cytosine that located in a CpG within an ETS motif. C, Summary of
the promoter DNA methylation pattern in ovarian cancer and normal tissues. The y-axis shows the mean methylation sites (each group n = 10).
Red circles show a methylation of cytosine that located in a CpG within an ETS motif. D, Overall methylation percentage within the promoter
region from ovarian cancer and normal tissues (each group n = 10). E, Correlation between the relative PARP1 mRNA levels and the total number
of methylated sites for each sample. Open circles, ovarian cancer tissues. Closed circles, normal ovarian tissues (each group n = 10). * P < 0.05
ovarian cancer vs. normal tissues.
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in Figure 2B and C, we searched for differences in the
DNA methylation pattern between ovarian cancer and
normal tissues. Bisulfite sequence analysis showed that
ovarian cancer tissues exhibited global hypomethylation,
especially around the ETS motif. The total percentage of
promoter methylated sites in this region (−190 to +496)
was significantly decreased in ovarian cancer compared
to normal tissues (P < 0.05; Figure 2D). In addition, we
noted a significant negative correlation between PARP1
mRNA levels and the total number of methylated sites
in both ovarian cancer and normal tissues (Figure 2E).Discussion
DNA methylation is an epigenetic phenomenon known to
play a critical role in regulating gene expression through
interference with the binding of specific transcription
factors to recognition sites in promoters [13]. ETS is one
of the largest transcription factor families and has a highly
conserved DNA-binding domain that recognizes a com-
mon sequence motif, 5’-(C/A) GGA (A/T) -3’ [14], which
is widely distributed in the PARP1 promoter [15]. The
present study showed that BRCA-mutated ovarian cancer
displayed a relatively hypomethylated PARP1 promoter,
but significantly higher methylation as noted particularly
around the ETS motif in normal ovarian tissue. Therefore,
we speculate that the important mechanism underlying
increased PARP1 expression might be related to the abnor-
mal methylation of CpG sites in the ETS motif, thereby
affecting the binding of ETS transcription factors. Previous
studies have shown that ETS transcription factors may be
key mediators in regulating PARP expression [15]. Further-
more, an increasing amount of evidence suggests that ETS
transcription factors are important regulators of the
tumorigenic properties of ovarian cancer cells [16] and
correlate poor survival in serous ovarian carcinoma [17].
Based on these findings, there are some interesting issues
that need to be considered in future studies. PARP1 can
enhance DNA methyltransferase 1 (DNMT1) expression
by maintaining the unmethylated state of the DNMT1 pro-
moter [18], so it can be predicted that up-regulation ex-
pression of DNMT1 may be beneficial in resisting
genome-wide demethylation during the progression of
ovarian cancer. Moreover, PARP1, as the protein compo-
nent of chromatin, controls transcription through affecting
the chromatin structure [19]. Therefore, PARP1 over-
expression may constitute a specific epigenetic mark in
BRCA-mutated ovarian cancer. Another report indicated
that hypermethylation of the BRCA1 promoter correlated
with gene inactivation in sporadic breast and ovarian
tumors, as inherited BRCA1 mutations [20]. Thus, it is im-
portant for future studies to analyze DNA methylation
patterns of the PARP1 promoter in the DNA methylation-associated inactivation of the BRCA1 gene in ovarian
cancer.
Conclusions
Our results indicate that the biological effects of ETS in
ovarian cancer might be mediated by the hypomethylated
ETS motif, which induces the high expression of PARP1.
Therefore, further studies are required to identify how the
methylation of ETS affects PARP1 transcription and
whether other factors could cooperate with ETS in con-
trolling PARP1 gene expression. If we can clarify the
mechanism behind high PARP1 expression from an epi-
genetic point of view, a more specific epigenetic therapy
could be developed for ovarian cancer.
Additional file
Additional file 1: Clinical characteristics for the 10 BRCA-mutated
serous ovarian cancer patients.
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